A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 18, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Steatohepatitis
Interventions
DRUG

Ontamalimab

Ontamalimab SC injection.

Trial Locations (15)

23298

VCU Dept of Internal Medicine, Division of GI, Hepatology & Nutrition, Richmond

28557

Lucas Research, Inc, Morehead City

33912

Covenant Metabolic Specialist LLC, Fort Myers

34240

Covenant Metabolic Specialist LLC, Sarasota

70072

Tandem Clinical Research GI, LLC, Marrero

75203

The Liver Institute at Methodist Dallas Medical Center, Dallas

77079

Houston Research Institute, Houston

78215

Texas Liver Institute, San Antonio

78229

Pinnacle Clinical Research LLC, San Antonio

85224

Arizona Liver Health, Chandler

85712

Adobe Clinical Research, LLC, Tucson

91105

California Liver Research Institute, Pasadena

92037

University of California, San Diego, NAFLD Research Center, La Jolla

92118

Southern California Research Center, Coronado

92377

Inland Empire Clinical Trials, LLC, Rialto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY